Impaired Oligodendrocyte Development Following Preterm Birth: Promoting GABAergic Action to Improve Outcomes
- PMID: 33634057
- PMCID: PMC7901941
- DOI: 10.3389/fped.2021.618052
Impaired Oligodendrocyte Development Following Preterm Birth: Promoting GABAergic Action to Improve Outcomes
Abstract
Preterm birth is associated with poor long-term neurodevelopmental and behavioral outcomes, even in the absence of obvious brain injury at the time of birth. In particular, behavioral disorders characterized by inattention, social difficulties and anxiety are common among children and adolescents who were born moderately to late preterm (32-37 weeks' gestation). Diffuse deficits in white matter microstructure are thought to play a role in these poor outcomes with evidence suggesting that a failure of oligodendrocytes to mature and myelinate axons is responsible. However, there remains a major knowledge gap over the mechanisms by which preterm birth interrupts normal oligodendrocyte development. In utero neurodevelopment occurs in an inhibitory-dominant environment due to the action of placentally derived neurosteroids on the GABAA receptor, thus promoting GABAergic inhibitory activity and maintaining the fetal behavioral state. Following preterm birth, and the subsequent premature exposure to the ex utero environment, this action of neurosteroids on GABAA receptors is greatly reduced. Coinciding with a reduction in GABAergic inhibition, the preterm neonatal brain is also exposed to ex utero environmental insults such as periods of hypoxia and excessive glucocorticoid concentrations. Together, these insults may increase levels of the excitatory neurotransmitter glutamate in the developing brain and result in a shift in the balance of inhibitory: excitatory activity toward excitatory. This review will outline the normal development of oligodendrocytes, how it is disrupted under excitation-dominated conditions and highlight how shifting the balance back toward an inhibitory-dominated environment may improve outcomes.
Keywords: GABA; glutamate; neurosteroids; oligodendrocyte; preterm (birth).
Copyright © 2021 Shaw, Crombie, Palliser and Hirst.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Examining Neurosteroid-Analogue Therapy in the Preterm Neonate For Promoting Hippocampal Neurodevelopment.Front Physiol. 2022 Apr 19;13:871265. doi: 10.3389/fphys.2022.871265. eCollection 2022. Front Physiol. 2022. PMID: 35514343 Free PMC article.
-
Reduced Neurosteroid Exposure Following Preterm Birth and Its' Contribution to Neurological Impairment: A Novel Avenue for Preventative Therapies.Front Physiol. 2019 May 15;10:599. doi: 10.3389/fphys.2019.00599. eCollection 2019. Front Physiol. 2019. PMID: 31156466 Free PMC article. Review.
-
Disruptions to the cerebellar GABAergic system in juvenile guinea pigs following preterm birth.Int J Dev Neurosci. 2018 Apr;65:1-10. doi: 10.1016/j.ijdevneu.2017.10.002. Epub 2017 Oct 9. Int J Dev Neurosci. 2018. PMID: 29024720
-
Neurosteroid replacement therapy using tiagabine and zuranolone restores cerebellar neurodevelopment and reduces hyperactive behaviour following preterm birth.J Dev Orig Health Dis. 2025 Jan 8;16:e2. doi: 10.1017/S2040174424000394. J Dev Orig Health Dis. 2025. PMID: 39773606
-
Loss of neurosteroid-mediated protection following stress during fetal life.J Steroid Biochem Mol Biol. 2016 Jun;160:181-8. doi: 10.1016/j.jsbmb.2015.09.012. Epub 2015 Sep 10. J Steroid Biochem Mol Biol. 2016. PMID: 26365557 Review.
Cited by
-
Protection from oxygen-glucose deprivation by neurosteroid treatment in primary neurons and oligodendrocytes.In Vitro Cell Dev Biol Anim. 2024 Oct;60(9):1068-1084. doi: 10.1007/s11626-024-00957-5. Epub 2024 Jul 29. In Vitro Cell Dev Biol Anim. 2024. PMID: 39075243 Free PMC article.
-
Examining Neurosteroid-Analogue Therapy in the Preterm Neonate For Promoting Hippocampal Neurodevelopment.Front Physiol. 2022 Apr 19;13:871265. doi: 10.3389/fphys.2022.871265. eCollection 2022. Front Physiol. 2022. PMID: 35514343 Free PMC article.
-
Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.JAMA. 2023 Aug 15;330(7):603-614. doi: 10.1001/jama.2023.12357. JAMA. 2023. PMID: 37581672 Free PMC article. Clinical Trial.
-
Quantitative Magnetic Resonance Imaging for Neurodevelopmental Outcome Prediction in Neonates Born Extremely Premature-An Exploratory Study.Clin Neuroradiol. 2024 Jun;34(2):421-429. doi: 10.1007/s00062-023-01378-9. Epub 2024 Jan 30. Clin Neuroradiol. 2024. PMID: 38289377 Free PMC article.
-
Effects of size at birth on health, growth and developmental outcomes in children up to age 18: an umbrella review.Arch Dis Child. 2023 Dec;108(12):956-969. doi: 10.1136/archdischild-2022-324884. Epub 2023 Jun 20. Arch Dis Child. 2023. PMID: 37339859 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous